Dermata Therapeutics, Inc. (DRMA) Stock Analysis

Dermata Therapeutics, Inc. (DRMA) Healthcare & Pipeline Overview

Dermata Therapeutics, Inc. is a clinical-stage biotechnology firm specializing in dermatological treatments, with a focus on acne, rosacea, psoriasis, hyperhidrosis, and aesthetic conditions. Their pipeline centers on DMT310 and DMT410, targeting significant unmet needs in medical and aesthetic dermatology, positioning them within a competitive biotechnology landscape.

What Is the Investment Thesis for DRMA?

Dermata Therapeutics presents a notable research candidate within the biotechnology sector, driven by its focus on dermatological treatments and its pipeline of clinical-stage product candidates. The company's lead candidate, DMT310, targeting acne and rosacea, addresses significant market needs. Successful completion of the Phase 2 trial for rosacea and advancement towards commercialization could serve as major catalysts. However, the company's small size and limited resources introduce risks associated with clinical trial outcomes and funding. The company's market capitalization is $0.00B, reflecting its early stage, and its beta of 0.67 suggests lower volatility compared to the broader market. Investors should closely monitor clinical trial results and regulatory milestones.

Based on FMP financials and quantitative analysis

DRMA Key Highlights

DMT310 has completed Phase IIb clinical trial for treatment of moderate-to-severe acne, indicating progress in addressing a common skin condition.

• DMT310 has completed Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, expanding its potential therapeutic applications.
• DMT310 is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea, a key milestone for potential market entry.
• DMT410 has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions, diversifying the product pipeline.
• The company was incorporated in 2014, marking over a decade of focus on dermatological solutions.

Who Are DRMA's Competitors?

DRMA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are DRMA's Key Strengths?

Focus on specific dermatological conditions allows for targeted research and development.

• DMT310 shows promise in treating acne and rosacea.
• Experienced management team with expertise in drug development.
• Proprietary technology platform.

What Are DRMA's Weaknesses?

Limited financial resources compared to larger pharmaceutical companies.

• Reliance on a small number of product candidates.
• High risk associated with clinical trials and regulatory approvals.
• Small number of employees (8).

What Could Drive DRMA Stock Higher?

Completion of Phase 2 clinical trial for DMT310 in the treatment of moderate-to-severe rosacea.

• Announcement of results from ongoing clinical trials.
• Potential partnerships or collaborations with larger pharmaceutical companies.
• Advancement of DMT410 into later-stage clinical trials.

What Are the Key Risks for DRMA?

Financial-distress signal — its Altman Z-Score of -24.78 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Unfavorable results from clinical trials.
• Regulatory delays or rejection of product candidates.
• Competition from established pharmaceutical companies.
• Limited financial resources to support ongoing research and development.
• Patent challenges or infringement claims.

What Are the Growth Opportunities for DRMA?

• Expansion into New Therapeutic Areas: Dermata has the opportunity to expand its pipeline beyond its current focus on acne, rosacea, psoriasis, hyperhidrosis, and aesthetic conditions. By identifying and developing treatments for other dermatological conditions, such as eczema or skin cancer, the company can broaden its market reach and revenue potential. Timeline: Ongoing, with continuous research and development efforts.
• Strategic Partnerships and Collaborations: Dermata can pursue strategic partnerships and collaborations with larger pharmaceutical companies or research institutions to accelerate the development and commercialization of its product candidates. These partnerships can provide access to additional funding, expertise, and resources, enhancing the company's ability to bring its products to market. The biotechnology industry is characterized by collaborations, and successful partnerships can significantly increase a company's value. Timeline: Ongoing, with active engagement in industry networking and partnering events.
• Geographic Expansion: Dermata has the potential to expand its market presence beyond the United States by seeking regulatory approval and commercializing its products in other regions, such as Europe and Asia. These regions represent significant market opportunities for dermatological treatments, driven by increasing awareness of skin health and rising disposable incomes. International expansion can diversify revenue streams and reduce reliance on the US market. Timeline: 3-5 years, contingent on regulatory approvals and market entry strategies.
• Leveraging DMT Platform for New Indications: Dermata can leverage its existing DMT platform to develop new product candidates for additional indications. By modifying the formulation or delivery of DMT310 and DMT410, the company can potentially address a wider range of dermatological conditions. This approach can reduce development costs and timelines compared to developing entirely new molecules. Timeline: 2-4 years, dependent on preclinical and clinical testing.
• Direct-to-Consumer Marketing: As the company's products approach commercialization, Dermata can explore direct-to-consumer marketing strategies to increase awareness and drive sales. This can involve online advertising, social media campaigns, and partnerships with dermatologists and other healthcare professionals. Direct-to-consumer marketing can be particularly effective for aesthetic treatments, where consumers are actively seeking solutions to improve their appearance. Timeline: 1-2 years, prior to product launch.

What Are DRMA's Competitive Advantages?

• Patented formulations and technologies that protect their product candidates from competition.
• Clinical trial data demonstrating the safety and efficacy of their products.
• Established relationships with key opinion leaders in dermatology.
• First-mover advantage in specific niche markets within dermatology.

What Does DRMA Do?

Dermata Therapeutics, Inc., established in 2014 and headquartered in San Diego, California, is a clinical-stage biotechnology company dedicated to the identification, development, and commercialization of innovative pharmaceutical product candidates for medical and aesthetic skin conditions. The company's primary focus is on addressing unmet needs in dermatology through targeted therapies. Dermata's lead product candidate, DMT310, is currently in a Phase 2 clinical trial for the treatment of moderate-to-severe rosacea and has completed a Phase IIb clinical trial for the treatment of moderate-to-severe acne, demonstrating its potential in addressing common skin disorders. Additionally, DMT310 has completed a Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis. The company is also developing DMT410, which has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions, expanding its portfolio to include both medical and cosmetic applications. Dermata Therapeutics operates within the highly competitive biotechnology sector, striving to bring novel solutions to the market for various dermatological conditions. The company's strategy involves rigorous clinical testing and strategic partnerships to advance its product candidates through the development pipeline and ultimately achieve commercial success.

What Products and Services Does DRMA Offer?

• Develop pharmaceutical product candidates for skin conditions.
• Focus on medical and aesthetic dermatology.
• Conduct clinical trials to evaluate the safety and efficacy of their products.
• Seek regulatory approval for their products from agencies like the FDA.
• Commercialize approved products through sales and marketing efforts.
• Research and identify new targets and therapies for skin diseases.
• Form strategic partnerships to accelerate development and commercialization.

How Does DRMA Make Money?

• Develop and patent novel pharmaceutical product candidates.
• Out-license or sell approved products to larger pharmaceutical companies.
• Generate revenue through product sales after regulatory approval.
• Potentially generate revenue through milestone payments from partnerships.

What Industry Does DRMA Operate In?

Dermata Therapeutics operates within the dynamic biotechnology industry, specifically targeting the dermatology market. This market is characterized by a growing demand for effective treatments for skin conditions such as acne, rosacea, psoriasis, and hyperhidrosis. The competitive landscape includes both large pharmaceutical companies and smaller biotech firms, all vying for market share with innovative therapies. Dermata's focus on DMT310 and DMT410 positions it to potentially capture a segment of this market, provided it can successfully navigate the clinical trial and regulatory approval processes. The biotechnology industry is characterized by high risk and high reward, with successful products generating significant revenue.

Who Are DRMA's Key Customers?

• Patients suffering from acne, rosacea, psoriasis, hyperhidrosis, and other skin conditions.
• Dermatologists and other healthcare professionals who prescribe or recommend their products.
• Hospitals and clinics that use their products in treatment protocols.
• Pharmaceutical companies that may license or acquire their products.

Over the past six months, Dermata Therapeutics, Inc. insiders filed 10 SEC Form 4 transactions — 1 sales and 9 purchases. On net that is roughly 4.9M shares acquired (about $4.8M) — insiders putting money in tends to read as conviction.

Dermata Therapeutics, Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 6.1% above estimates on average.

Dermata Therapeutics, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -24.78 places it in the distress zone, a signal of elevated financial risk.

Key Financial Metrics

Return on assets is -95.1%, showing how much profit it generates from its asset base. A current ratio of 7.09 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -142.7%, the inverse of the P/E and a quick read on earnings relative to price.

DRMA Revenue & Earnings Trend

In Q2 FY2026, DRMA generated $0 in top-line revenue. The company recorded a net loss of $3.0M, with diluted EPS of $-0.74. Quarter-over-quarter revenue has been mixed, typical for a unknown company operating in Healthcare. Across the four most recent quarters, DRMA averaged $-1.10 in diluted EPS.

Company Profile

Dermata Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Diego, US. The company is led by CEO Gerald T. Proehl. DRMA has traded publicly since 2021.

DRMA Financials

DRMA Latest News

DRMA Analyst Consensus

DRMA MoonshotScore

Common Questions About DRMA (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources